U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Medical Devices
  3. Products and Medical Procedures
  4. In Vitro Diagnostics
  5. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)
  1. In Vitro Diagnostics

List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)

A companion diagnostic device can be in vitro diagnostic (IVD) device or an imaging tool that provides information that is essential for the safe and effective use of a corresponding therapeutic product. Below is a table of cleared or approved companion diagnostic devices (in vitro and imaging).

The use of an IVD companion diagnostic device is stipulated in the instructions for use in the labeling of the diagnostic device. The IVD companion diagnostic devices included in the first table below are indicated for a specific therapeutic product(s). Some IVD companion diagnostic devices are indicated for a specific group of oncology therapeutic products (see FDA's guidance document, Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products, for more information on group labeling). The second table below lists companion diagnostic devices with group labeling indications.

In addition, the use of an IVD companion diagnostic device is stipulated in the labeling of the therapeutic product, as well as in the labeling of any generic equivalents and biosimilar equivalents of the therapeutic product. In all cases, the therapeutic product label should be referenced for specific information about the use of the therapeutic, including use of a corresponding companion diagnostic.

For a list of all FDA cleared or approved nucleic acid based tests, see Nucleic Acid Based Tests.

Please submit any questions to DICE@fda.hhs.gov.

List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools)

Diagnostic Name (Manufacturer)Indication - Sample TypeDrug Trade Name (Generic) NDA / BLABiomarker(s)Biomarker(s) (Details)PMA / 510(k) /
513(f)(2) / HDE (Approval / Clearance / Grant Date)
therascreen PDGFRA RGQ PCR Kit (QIAGEN GmbH)Gastrointestinal Stromal Tumors (GIST) - TissueAYVAKIT (Avapritinib) NDA 212608PDGFRAD842V mutationP210002 (06/29/2023)
Abbott RealTime IDH1 (Abbott Molecular, Inc.)Acute Myeloid Leukemia - Peripheral Blood or Bone MarrowTibsovo (ivosidenib) NDA 211192IDH1R132 mutations (R132C, R132H, R132G, R132S, and R132L)P170041
(07/20/2018)
Abbott RealTime IDH1 (Abbott Molecular, Inc.)Myelodysplastic Syndromes (MDS) - Peripheral Blood or Bone MarrowTibsovo (ivosidenib) NDA 211192IDH1R132 mutations (R132C, R132H, R132G, R132S, and R132L)P170041/S007
(10/24/2023)
Abbott RealTime IDH2 (Abbott Molecular, Inc.)Acute Myeloid Leukemia - Peripheral Blood or Bone MarrowIdhifa (enasidenib) NDA 209606IDH2R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172WP170005
(08/01/2017)
Bond Oracle HER2 IHC System (Leica Biosystems)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2 protein overexpressionP090015
(04/18/2012)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Ovarian Cancer - Whole BloodLynparza (olaparib) NDA 208558BRCA1 and BRCA2MutationsP140020
(12/19/2014)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Breast Cancer - Whole BloodLynparza (olaparib) NDA 208558BRCA1 and BRCA2MutationsP140020/S012
(01/12/2018)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Breast Cancer - Whole BloodTalzenna (talazoparib) NDA 211651BRCA1 and BRCA2MutationsP140020/S015
(10/16/2018)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Ovarian Cancer - Whole BloodRubraca (rucaparib) NDA 209115BRCA1 and BRCA2MutationsP140020/S016
(10/16/2018)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Pancreatic Cancer - Whole BloodLynparza (olaparib) NDA 208558BRCA1 and BRCA2MutationsP140020/S019
(12/27/2019)
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - Whole BloodLynparza (olaparib) NDA 208558BRCA1 and BRCA2MutationsP140020/S020
(05/19/2020)
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)Melanoma - TissueZelboraf (vemurafenib) NDA 202429BRAFV600EP110020
(08/17/2011)
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)Melanoma - TissueCotellic (cobimetinib) NDA 206192 in combination with Zelboraf (vemurafenib) NDA 202429BRAFV600E or V600KP110020/S016
(11/07/2016)
cobas EGFR Mutation Test v1 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTarceva (erlotinib) NDA 021743EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019
(07/15/2013)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTagrisso (osimertinib) NDA 208065EGFR (HER1)T790MP120019/S007
(11/13/2015)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTagrisso (osimertinib) NDA 208065EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S016
(04/18/2018)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTagrisso (osimertinib) NDA 208065EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S018
(04/18/2018)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S019
(08/22/0218)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S031
(10/27/2020)
Group Labeling, see table below
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaTarceva (erlotinib) NDA 021743EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S031
(10/27/2020)
Group Labeling, see table below
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaGilotrif (afatinib) NDA 201292EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S031
(10/27/2020)
Group Labeling, see table below
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaTagrisso (osimertinib) NDA 208065EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120019/S031
(10/27/2020)
Group Labeling, see table below
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTagrisso (osimertinib) NDA 208065EGFR (HER1)T790MP150044
(09/28/2016)
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTarceva (erlotinib) NDA 021743EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP150047
(06/01/2016)
cobas EZH2 Mutation Test (Roche Molecular Systems, Inc.)Follicular Lymphoma Tumor - TissueTazverik (tazemetostat) NDA 213400EZH2Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 geneP200014
(06/18/2020)
cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084KRASMutations in codons 12 and 13 of KRAS geneP140023
(05/07/2015)
cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)Colorectal Cancer - TissueVectibix (panitumumab) BLA 125147KRASMutations in codons 12 and 13 of KRAS geneP140023
(05/07/2015)
Dako EGFR pharmDx Kit (Dako North America, Inc.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084EGFR (HER1)EGFR (HER1) protein expressionP030044
(02/12/2004)
Dako EGFR pharmDx Kit (Dako North America, Inc.)Colorectal Cancer - TissueVectibix (panitumumab) BLA 125147EGFR (HER1)EGFR (HER1) protein expressionP030044/S002
(09/27/2006)
FerriScan (Resonance Health Analysis Services Pty Ltd)Non-Transfusion-Dependent Thalassemia - TissueExjade (deferasirox) NDA 021882Liver iron concentration imagingLiver iron concentration based on the proton transverse relaxation rate of MRI imagesDEN130012 / K124065
(01/23/2013)
FoundationFocus CDxBRCA Assay (Foundation Medicine, Inc.)Ovarian Cancer - TissueRubraca (rucaparib) NDA 209115BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP160018
(12/19/2016)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueGilotrif (afatinib) NDA 201292EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTarceva (erlotinib) NDA 021743EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTagrisso (osimertinib) NDA 208065EGFR (HER1)T790MP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueAlecensa (alectinib) NDA 208434ALKALK rearrangementsP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueXalkori (crizotinib) NDA 202570ALKALK rearrangementsP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueZykadia (ceritinib) NDA 211225ALKALK rearrangementsP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTafinlar (dabrafenib) NDA 202806 in combination with Mekinist (trametinib) NDA 204114BRAFV600EP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)ERBB2 (HER2) amplificationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Breast Cancer - TissuePerjeta (pertuzumab) BLA 125409ERBB2 (HER2)ERBB2 (HER2) amplificationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Breast Cancer - TissueKadcyla (ado-trastuzumab emtansine) BLA 125427ERBB2 (HER2)ERBB2 (HER2) amplificationP170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084KRASKRAS wild-type (absence of mutations in codons 12 and 13)P170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Colorectal Cancer - TissueVectibix (panitumumab) BLA 125147KRAS and NRASKRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)P170019
(11/30/2017)
FoundationOne CDx (Foundation Medicine, Inc.)Melanoma - TissueMekinist (trametinib) NDA 204114BRAFV600E and V600KP170019
(11/30/2017)
Group Labeling, See table below
FoundationOne CDx (Foundation Medicine, Inc.)Ovarian Cancer - TissueLynparza (olaparib) NDA 208558BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP170019/S004
(07/01/2019)
FoundationOne CDx (Foundation Medicine, Inc.)Breast Cancer - TissuePiqray (alpelisib) NDA 212526PIK3CAC420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047YP170019/S006
(12/03/2019)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTagrisso (osimertinib) NDA 208065EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP170019/S008
(07/01/2019)
Group Labeling, See table below
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTabrecta (capmatinib) NDA 213591METMET single nucleotide variants and indels that lead to MET exon 14 skippingP170019/S011
(05/06/2020)
FoundationOne CDx (Foundation Medicine, Inc.)Cholangiocarcinoma - TissuePemazyre (pemigatinib) NDA 213736FGFR2FGFR2 fusions and select rearrangementsP170019/S013
(04/17/2020)
FoundationOne CDx (Foundation Medicine, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - TissueLynparza (olaparib) NDA 208558Homologous recombination repair (HRR) genesBRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterationsP170019/S015
(05/19/2020)
FoundationOne CDx (Foundation Medicine, Inc.)Solid Tumors - TissueKeytruda (pembrolizumab) BLA 125514TMBTMB ≥ 10 mutations per megabaseP170019/S016
(06/16/2020)
FoundationOne CDx (Foundation Medicine, Inc.)Solid Tumors - TissueVitrakvi (larotrectinib) NDA 210861NTRK1, NTRK2 and NTRK3NTRK1, NTRK2 and NTRK3 fusionsP170019/S017
(10/23/2020)
FoundationOne CDx (Foundation Medicine, Inc.)Solid Tumors - TissueKeytruda (pembrolizumab) BLA 125514MSI-HighMicrosatellite instability-High (MSI-H)P170019/S029
(02/18/2022)
FoundationOne CDx (Foundation Medicine, Inc.)    Solid Tumors - Tissue    Rozlytrek (entrectinib) 
NDA 212725
NTRK1, NTRK2 and NTRK3    NTRK1, NTRK2 and NTRK3 fusionsP170019/S014 
(06/07/2022)
FoundationOne CDx (Foundation Medicine, Inc.)    Non-Small Cell Lung Cancer (NSCLC) - TissueRozlytrek (entrectinib) 
NDA 212725
ROS1ROS1 fusionsP170019/S014 
(06/07/2022)
FoundationOne CDx (Foundation Medicine, Inc.)Melanoma - TissueTecentriq (atezolizumab) BLA 761034 in combination with Cotellic (cobimetinib) NDA 206192 and Zelboraf (vemurafenib) NDA 202429BRAFBRAF V600 mutationsP170019/S030
(01/19/2022)
FoundationOne CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueBRAFTOVI (encorafenib) NDA210496 in combination with MEKTOVI (binimetinib) NDA210498BRAFV600EP170019/S039
(10/11/2023)
FoundationOne CDx (Foundation Medicine, Inc.)Solid Tumors - TissueRETEVMO (selpercatinib) NDA214246RETRET fusionsP170019/S043
(10/06/2023)
 
FoundationOne CDx (Foundation Medicine, Inc.)Breast Cancer - TissueTRUQAP (capivasertib) NDA218197 in combination with FASLODEX (fulvestrant) NDA021344PIK3CAAKT1/PTEN alterationsP170019/S048
(11/16/2023)
 
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP190032
(08/26/2020)
P190032/S008
(12/19/2022)
Group Labeling, See table below
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTagrisso (osimertinib) NDA 208065EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP190032
(08/26/2020)
P190032/S008
(12/19/2022)
Group Labeling, See table below
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTarceva (erlotinib) NDA 021743EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP190032
(08/26/2020)
P190032/S008
(12/19/2022)
Group Labeling, See table below
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaBRAFTOVI (encorafenib) NDA210496 in combination with MEKTOVI (binimetinib) NDA210498BRAFV600EP190032/S011
(10/11/2023)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - PlasmaRubraca (rucaparib) NDA 209115BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP190032
(08/26/2020)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTabrecta (capmatinib) NDA 213591METMET single nucleotide variants and indels that lead to MET exon 14 skippingP190032/S001
(07/15/2021)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaRozlytrek (entrectinib) NDA 212725ROS1ROS1 fusionsP190032/S004
(12/22/2022)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Solid Tumors - PlasmaRozlytrek (entrectinib) NDA 212725NTRK1, NTRK2, and NTRK3 fusionsNTRK1/2/3 fusionsP190032/S004
(12/22/2022)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaAlecensa (alectinib) NDA 208434ALKALK rearrangementsP200006
(10/26/2020)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Breast Cancer - PlasmaPiqray (alpelisib) NDA 212526PIK3CAC420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047YP200006
(10/26/2020)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - PlasmaLynparza (olaparib) NDA 208558BRCA1, BRCA2 and ATMBRCA1, BRCA2, and ATM alterationsP200006
(10/26/2020)
Guardant360 CDx (Guardant Health, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaTagrisso (osimertinib) NDA 208065EGFR (HER1)EGFR exon 19 deletions, EGFR exon 21 L858R, and T790MP200010
(08/07/2020)
Guardant360 CDx (Guardant Health, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaRybrevant (amivantamb) BLA 761210EGFR (HER1)EGFR exon 20 insertionsP200010/S001
(05/21/2021)
Guardant360 CDx (Guardant Health, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaLumakras (sotorasib) NDA 214665KRASG12CP200010/S002
(05/28/2021)
Guardant360 CDx (Guardant Health, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaENHERTU (fam-trastuzumab deruxtecan-nxki) BLA 761139ERBB2ERBB2 Activating Mutations (SNVs And Exon 20 Insertions)P200010/S008
(08/11/2022)
Guardant360 CDx (Guardant Health, Inc.)Breast Cancer - PlasmaOrserdu (elacestrant) NDA 217639ESR1ESR1 missense mutations between codons 310 and 547P200010/S010
(01/27/2023)
HER2 CISH pharmDx Kit (Dako Denmark A/S)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP100024
(11/30/2011)
HER2 FISH pharmDx Kit (Dako Denmark A/S)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP040005
(05/03/2005)
HER2 FISH pharmDx Kit (Dako Denmark A/S)Gastric and Gastroesophageal Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP040005/S005
(10/20/2010)
HER2 FISH pharmDx Kit (Dako Denmark A/S)Breast Cancer - TissuePerjeta (pertuzumab) BLA 125409ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP040005/S006
(06/08/2012)
HER2 FISH pharmDx Kit (Dako Denmark A/S)Breast Cancer - TissueKadcyla (ado-trastuzumab emtansine) BLA 125427ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP040005/S009
(02/22/2013)
HercepTest (Dako Denmark A/S)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2 protein overexpressionP980018
(09/25/1998)
HercepTest (Dako Denmark A/S)Gastric and Gastroesophageal Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2 protein overexpressionP980018/S010
(10/20/2010)
HercepTest (Dako Denmark A/S)Breast Cancer - TissuePerjeta (pertuzumab) BLA 125409ERBB2 (HER2)HER-2 protein overexpressionP980018/S015
(06/08/2012)
HercepTest (Dako Denmark A/S)Breast Cancer - TissueKadcyla (ado-trastuzumab emtansine) BLA 125427ERBB2 (HER2)HER-2 protein overexpressionP980018/S016
(02/22/2013)
INFORM HER-2/neu (Ventana Medical Systems, Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP940004
(12/30/1997)
InSite Her-2/neu (CB11) Monoclonal Antibody (Biogenex Laboratories, Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER2protein overexpressionP040030
(12/22/2004)
KIT D816V Assay (ARUP Laboratories, Inc.)Aggressive Systemic Mastocytosis - Bone MarrowGleevec (imatinib mesylate) NDA 021588KITD816VH140006
(12/18/2015)
LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)Acute Myelogenous Leukemia - Peripheral Blood or Bone MarrowRydapt (midostaurin) NDA 207997FLT3 (ITD/TDK)ITD mutations and TKD mutations D835 and I836P160040
(04/28/2017)
LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)Acute Myelogenous Leukemia - Peripheral Blood or Bone MarrowXospata (gilterinib) NDA 211349FLT3 (ITD/TDK)ITD mutations and TKD mutations D835 and I836P160040/S002
(11/28/2018)
MRDx BCR-ABL Test (MolecularMD Corporation)Chronic Myeloid Leukemia - Peripheral BloodTasigna (nilotinib) NDA 022068t(9;21) Philadelphia chromosomeBCR-ABL fusionK173492
(12/22/2017)
Myriad myChoice CDx (Myriad Genetic Laboratories, Inc.)Ovarian Cancer - TissueLynparza (olaparib) NDA 208558Myriad HRDDeleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score)P190014/S003
(05/08/2020)
nAbCyte Anti-AAVRh74var HB-FE Assay (Labcorp Drug Development)Moderate to severe Hemophilia B patients - SerumBEQVEZ (fidanacogene elaparvovec) BLA 125786
 
AAVRh74var capsid neutralizing antibodiesNeutralizing antibodies to the adeno-associated virus serotype Rh74var (AAVRh74var) capsidH230005
(04/25/2024)
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084KRASKRAS wild-type (absence of mutations in codons 12 and 13)P200011
(07/30/2021)
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)Colorectal Cancer - TissueVectibix (panitumumab) BLA 125147KRASKRAS wild-type (absence of mutations in codons 12 and 13)P200011
(07/30/2021)
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueA tyrosine kinase inhibitor approved by FDA for that indicationEGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP200011
(07/30/2021)
Group Labeling, See table below
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueTafinlar (dabrafenib) NDA 202806 in combination with Mekinist (trametinib) NDA 204114BRAFV600EP160045
(06/22/2017)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueXalkori (crizotinib) NDA 202570ROS1ROS1 fusionsP160045
(06/22/2017)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP160045
(06/22/2017)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueGavreto (pralsetinib) NDA 213721RETRET fusionsP160045/S019
(09/04/2020)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueRybrevant (amivantamb) BLA 761210EGFR (HER1)Exon 20 insertion mutationsP160045/S027
(12/01/2021)
Oncomine Dx Target Test (Life Technologies Corporation)Cholangiocarcinoma - TissueTibsovo (ivosidenib) NDA 211192IDH1Single nucleotide variantsP160045/S028
(08/25/2021)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueENHERTU (fam-trastuzumab deruxtecan-nxki) BLA 761139ERBB2ERBB2 Activating Mutations (SNVs And Exon 20 Insertions)P160045/S035
(08/11/2022)
Oncomine Dx Target Test (Life Technologies Corporation)Non-Small Cell Lung Cancer (NSCLC) - TissueRetevmo (selpercatinib) NDA 213246RETRET fusionsP160045/S031
(09/21/2022)
Oncomine Dx Target Test (Life Technologies Corporation)Medullary Thyroid Cancer (MTC) - TissueRetevmo (selpercatinib) NDA 213246RETRET mutations (SNVs, MNVs, and deletions)P160045/S031
(09/21/2022)
Oncomine Dx Target Test (Life Technologies Corporation)Thyroid Cancer (TC) - TissueRetevmo (selpercatinib) NDA 213246RETRET fusionsP160045/S031
(09/21/2022)
PathVysion HER-2 DNA Probe Kit (Abbott Molecular Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP980024
(12/11/1998)
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2 protein overexpressionP990081
(11/28/2000)
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)Breast Cancer - TissueKadcyla (ado-trastuzumab emtansine) BLA 125427ERBB2 (HER2)HER-2 protein overexpressionP990081/S039
(05/03/2019)
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)Breast Cancer - TissueEnhertu (fam-trastuzumab deruxtecan-nxki) BLA 761139ERBB2 (HER2)HER-2 protein overexpressionP990081/S047
(09/30/2022)
PDGFRB FISH Assay (ARUP Laboratories, Inc.)Myelodysplastic Syndrome/Myeloproliferative Disease - Bone MarrowGleevec (imatinib mesylate) NDA 021588PDGFRBPDGFRB gene rearrangement at 5q31~33H140005
(12/18/2015)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013
(10/02/2015)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Cervical Cancer - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013/S009
(06/12/2018)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Head and Neck Squamous Cell Carcinoma (HNSCC) - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013/S014
(06/10/2019)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Esophageal Squamous Cell Carcinoma (ESCC) - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013/S016
(07/30/2019)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Triple-Negative Breast Cancer (TNBC) - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013/S020
(11/13/2020)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueLibtayo (cemiplimab-rwlc) BLA 761097PD-L1PD-L1 protein expression [Tumor Proportion Score (TPS) ≥ 50%]P150013/S021
(02/22/2021)
PD-L1 IHC 28-8 pharmDx (Dako North America, Inc.)Non-small cell lung cancer (NSCLC) - TissueOpdivo (nivolumab) BLA 125554 in combination with Yervoy (ipilimumab) BLA 125377PD-L1PD-L1 protein expression (tumor cell staining ≥1%)P150025/S013
(05/15/2020)
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - TissueKeytruda (pembrolizumab) BLA 125514PD-L1PD-L1 protein expressionP150013/S027
(11/07/2023)
POMC/PCSK1/LEPR CDx Panel (PreventionGenetics, LLC)Obesity - Blood or SalivaImcivree (setmelanotide acetate) NDA 213793POMC, PCSK1 and LEPRVariants (Pathogenic/Likely Pathogenic) and Variants of Uncertain SignificanceDEN200059
(01/21/2022)
SeCore CDx HLA Sequencing System (One Lambda Inc.)Uveal Melanoma – Whole BloodKimmtrak (tebentafusp-tebn) BLA 761228HLAHLA-A*02:01BR220737
(11/28/2022)
SPOT-LIGHT HER2 CISH Kit (Life Technologies Corporation)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP050040
(07/01/2008)
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueGilotrif (afatinib) NDA 201292EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120022
(07/12/2013)
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueIressa (gefitinib) NDA 206995EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120022/S001
(07/10/2015)
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueGilotrif (afatinib) NDA 201292EGFR (HER1)L861Q, G719X and S7681P120022/S016
(01/12/2016)
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueVizimpro (dacomitinib) NDA 211288EGFR (HER1)Exon 19 deletion or exon 21 L858R substitution mutationP120022/S018
(09/27/2018)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Colorectal Cancer - TissueVectibix (panitumumab) BLA 125147KRASG12A, G12D, G12R, G12C, G12S, G12V, G13DP110027
(05/23/2014)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueLumakras (sotorasib) NDA 214665KRASG12CP110027/S012
(05/28/2021)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084KRASG12A, G12D, G12R, G12C, G12S, G12V, G13DP110030
(07/06/2012)
therascreen BRAF V600E RGQ PCR Kit (QIAGEN GmbH)Colorectal Cancer - TissueBraftovi (encorafenib) NDA 210496 in combination with Erbitux (cetuximab) BLA 125084BRAFV600EP190026
(04/15/2020)
therascreen FGFR RGQ RT-PCR Kit (QIAGEN Manchester Ltd.)Urothelial Cancer - TissueBalversa (erdafitinib) NDA 212018FGFR3Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)P180043
(04/12/2019)
therascreen PIK3CA RGQ PCR Kit (QIAGEN GmbH)Breast Cancer - Tissue or PlasmaPiqray (alpelisib) NDA 212526PIK3CAC420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047YP190001
(05/24/2019)
P190004
(05/24/2019)
THXID BRAF Kit (bioMérieux Inc.)Melanoma - TissueMekinist (trametinib) NDA 204114BRAFV600E or V600KP120014
(05/29/2013)
THXID BRAF Kit (bioMérieux Inc.)Melanoma - TissueTafinlar (dabrafenib) NDA 202806BRAFV600EP120014
(05/29/2013)
THXID BRAF Kit (bioMérieux Inc.)Melanoma - TissueBraftovi (encorafenib) NDA 210496 in combination with Mektovi (binimetinib) NDA 210498BRAFV600E or V600KP120014/S008
(06/27/2018)
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueXalkori (crizotinib) NDA 202570ALKALK protein expressionP140025
(06/12/2015)
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueZykadia (ceritinib) NDA 211225ALKALK protein expressionP140025/S005
(05/26/2017)
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueAlecensa (alectinib) NDA 208434ALKALK protein expressionP140025/S006
(11/06/2017)
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueLorbrena (lorlatinib) NDA 210868ALKALK protein expressionP140025/S014
(03/03/2021)
Ventana FOLR1 (FOLR-2.1) RxDx Assay 
(Ventana Medical Systems, Inc.)    
Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - Tissue    Elahere (mirvetuximab soravtansine-gynx) BLA 761310FOLR1FOLR1 protein expression    P220006 
(11/14/2022)
Ventana HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc.)Breast Cancer - TissueHerceptin (trastuzumab) BLA 103792ERBB2 (HER2)HER-2/neu (ERBB2) gene amplificationP190031
(07/28/2020)
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)Endometrial Carcinoma (EC) - TissueJemperli (dostarlimag-gxly) NDA 761174deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6P200019
(04/22/2021)
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)Solid TumorsKeytruda (pembrolizumab) BLA 125514deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2 and MSH6P210001/S001 
(03/21/2022)
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)Endometrial Carcinoma (EC) - TissueKeytruda (pembrolizumab) BLA 125514 in combination with Lenvima (lenvatinib) NDA 206947proficient mismatch repair (pMMR) proteins MLH1, PMS2, MSH2 and MSH6P210001/S002
(06/16/2022)
Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)Urothelial Carcinoma - TissueTecentriq (atezolizumab) BLA 761034PD-L1PD-L1 protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area)P160002
(05/18/2016)
Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueTecentriq (atezolizumab) BLA 761034PD-L1PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%])P160002/S006
(07/02/2018)
Ventana PD-LI (SP263) Assay (Ventana Medical Systems, Inc)Non-Small Cell Lung Cancer (NSCLC) - TissueTecentriq (atezolizumab) BLA 761034PD-L1PD-L1 protein expressionP160046/S010
(10/15/2021)
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueXalkori (crizotinib) NDA 202570ALKALK gene rearrangementsP110012
(08/26/2011)
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueAlunbrig (brigatinib) NDA 208772ALKALK gene rearrangementsP110012/S020
(05/22/2020)
Vysis CLL FISH Probe Kit (Abbott Molecular, Inc.)B-cell Chronic Lymphocytic Leukemia - Peripheral BloodVenclexta (venetoclax) NDA 208573TP53Deletion chromosome 17p (17p-)P150041
(04/11/2016)
Abbott RealTime IDH1 (Abbott Molecular, Inc.)Acute Myeloid Leukemia - Peripheral Blood or Bone MarrowRezlidhia (olutasidenib) NDA 215814IDH1R132 mutations (R132C, R132H, R132G, R132S, and R132L)P170041/S006
(12/01/2022)
Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.)Non-Small Cell Lung Cancer (NSCLC) - PlasmaKrazati (adagrasib) NDA 216340KRASKRAS G12CP210040
(12/12/2022)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Colorectal Cancer - TissueErbitux (cetuximab) BLA 125084KRASKRAS wild-type (absence of mutations in codons 12 and 13)P110027/S013
(12/02/2022)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Non-Small Cell Lung Cancer (NSCLC) - TissueKrazati (adagrasib) NDA 216340KRASKRAS G12CP110027/S013
(12/02/2022)
xT CDx (Tempus Labs, Inc.)Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva)Erbitux (cetuximab) BLA 125084KRASKRAS wild-type (absence of mutations in codons 12 or 13)P210011 (04/28/2023)
xT CDx (Tempus Labs, Inc.)Colorectal Cancer (CRC) - Tissue (Matching Blood/Saliva)Vectibix (panitumumab) BLA 125147KRAS and NRASKRAS wild-type (absence of mutations in exons 2, 3, or 4) and NRAS wild-type (absence of mutations in exons 2, 3, or 4)P210011 (04/28/2023)
AAV5 DetectCDx (ARUP Laboratories)Hemophilia A Patients - PlasmaROCTAVIAN (valoctocogene roxaparvovec-rvox) BLA 125720Anti-AAV5 AntibodiesAntibodies to the adeno-associated virus serotype 5 (AAV5) viral vectorP190033 (06/29/2023)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Metastatic Colorectal Cancer (mCRC) - PlasmaBRAFTOVI (encorafenib) NDA 210496 in combination with cetuximab BLA 125084BRAFBRAF V600E alterationP190032/S010 (06/08/2023)
LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)Acute Myelogenous Leukemia (AML) - Peripheral Blood or Bone MarrowVANFLYTA (quizartinib) NDA 216993FLT3 (ITD/TDK)IDT mutations and TKD mutations D835 and I836P160040/S011 (07/20/2023)
FoundationOne CDx 
(Foundation Medicine, Inc.)
Prostate Cancer - TissueAKEEGA (niraparib + abiraterone acetate) NDA 216793BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP170019/S042 
(08/11/2023)
CRCDx RAS Mutation Detection Assay Kit (EntroGen, Inc.)Colorectal Cancer (CRC) - TissueVectibix (panitumumab) BLA 125147KRAS and NRASKRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4) and NRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4)P220005 (09/29/2023)
Oncomine Dx Target Test (Life Technologies Corporation)Anaplastic Thyroid Cancer (ATC) - TissueTafinlar (dabrafenib) NDA 202806 in combination with Mekinist (trametinib) NDA 204114BRAFBRAF V600E mutationsP160045/S025 (09/29/2023)
SeCore CDx HLA Sequencing System (One Lambda, Inc.)Synovial sarcoma – Whole blood    Tecelra (afamitresgene autoleucel) - BLA 125789HLA

Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles.

Exclusion alleles: HLA-A*02:05 and its P-group alleles.    

BK241074 
(08/01/2024)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)    Metastatic Castrate Resistant Prostate Cancer (mCRPC) - plasma    AKEEGA (niraparib +abiraterone acetate)    
NDA 216793
BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP190032/S014       
(06/28/ 2024)
TruSight Oncology Comprehensive (Illumina, Inc.)    Solid Tumors - TissueVitrakvi (larotrectinib) NDA 210861NTRK1, NTRK2, and NTRK3 fusionsNTRK1/2/3 fusionsP230011 
(08/21/2024)
TruSight Oncology Comprehensive (Illumina, Inc.)Non-Small Cell Lung Cancer (NSCLC) – TissueRetevmo (selpercatinib) NDA 213246RETRET fusionsP230011 
(08/21/2024)
MAGE-A4 IHC 1F9 pharmDx (Agilent Technologies, Inc.)    Synovial sarcoma - TissueTecelra (afamitresgene autoleucel) – BLA 125789Melanoma-associated antigen 4 (MAGE-A4)MAGE-A4 protein overexpressionP230016
(08/01/2024)
Oncomine Dx Target Test (Life Technologies Corporation)Astrocytoma and Oligodendroglioma - TissueVORANIGO (vorasidenib) – NDA 218784IDH1, IDH2IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutationsP160045/S046
(09/18/2024)
Ventana PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.)Non-Small Cell Lung Cancer (NSCLC) – TissueLibtayo (cemiplimab-rwlc) – BLA 761097PD-L1PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC  50%])P160046/S013
(03/01/2023)
FoundationOne CDx (Foundation Medicine, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - TissueLynparza (olaparib) NDA 208558 in combination with abiraterone BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP170019/S052
(08/30/2024)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Metastatic Castrate Resistant Prostate Cancer (mCRPC) - PlasmaLynparza (olaparib) NDA 208558 in combination with abiraterone BRCA1 and BRCA2BRCA1 and BRCA2 alterationsP190032/S016
(08/30/2024)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)Breast Cancer - PlasmaITOVEBI (inavolisib) NDA 219249 in combination with palbociclib and fulvestrant PIK3CAMutationsP190032/S023
(10/10/2024)
VENTANA CLDN18 (43-14A) RxDx Assay (Ventana Medical Systems, Inc.)Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma - TissueVYLOY (zolbetuximab) – BLA 761365Claudin 18 (CLDN18)Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining) P230018
(10/18/2024)
FoundationOne Liquid CDx (Foundation Medicine, Inc.)    Non-Small Cell Lung Cancer (NSCLC) - Plasma    Tepmetko (tepotinib) – NDA 214096METMET single nucleotide variants and indels that lead to MET exon 14 skippingP190032/S015 
(11/14/2024)
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)Colorectal Cancer - TissueKrazati (adagrasib) in combination with Erbitux (cetuximab) – NDA 216340KRASKRAS G12CP110027/S017 
(06/21/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Breast Cancer - TissuePiqray (alpelisib) – NDA 212526PIK3CAC420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047YP240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Colorectal Cancer - TissueVectibix (panitumumab) – BLA 125147KRAS and NRASKRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4) and NRAS wild-type biomarkers (the absence of mutations in exons 2, 3, or 4)P240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Colorectal Cancer - TissueBRAFTOVI (encorafenib) NDA 210496 in combination with ERBITUX (cetuximab) BLA 125084BRAFV600EP240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Melanoma - TissueMekinist (trametinib) NDA 204114BRAFV600E or V600KP240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Solid Tumors - TissueKeytruda (pembrolizumab) BLA 125514MSI-HighMicrosatellite instability – High (MSI-H)P240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Solid Tumors - TissueJemperli (dostarlimab-gxly) – BLA 761223MSI-HighMicrosatellite instability – High (MSI-H)P240010 
(11/05/2024)
MI Cancer Seek (MCS) (Caris Life Sciences)Endometrial Carcinoma (EC) - TissueKeytruda (pembrolizumab) BLA 125514 in combination with Lenvima (lenvatinib) NDA 206947Not MSI-HighNot Microsatellite instability-high (Not MSI-H)P240010 
(11/05/2024)
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)Biliary Tract Cancer (gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma) - TissueZiihera (zanidatamab-hrii) – BLA 761416ERBB2 
(HER2)
HER-2 protein overexpressionP990081/S054 
(11/20/2024)
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)Solid TumorsJemperli (dostarlimag-gxly) BLA 761174Deficient mismatch repair (dMMR) proteinsMLH1, PMS2, MSH2, and MSH6P210001 
(08/17/2021)

Device Indication for a Specific Group of Oncology Therapeutic Products

Diagnostic Name
(Manufacturer)
Indication(s) - Sample TypePMA (Approval Date)Device Indication for a Specific Group of Oncology Therapeutic Products and Trade Name (Generic) – NDA/BLA
cobas EGFR Mutation Test v2
(Roche Molecular Systems, Inc.)
Non-Small Cell Lung Cancer (NSCLC) - Tissue or PlasmaP120019/S031
(10/27/2020)

Non-small cell lung cancer (tissue):

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

Non-small cell lung cancer (plasma):

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

FoundationOne CDx
(Foundation Medicine, Inc.)
Melanoma - TissueP170019/S025
(11/10/2021)

"Identifying patients with melanoma whose tumors have BRAF V600E and are suitable for treatment with BRAF Inhibitors approved by FDA for that indication"

List of BRAF Inhibitors approved by FDA for this indication:

"Identifying patients with melanoma whose tumors have BRAF V600E and V600K and are suitable for treatment with BRAF/MEK Inhibitor Combinations approved by FDA for that indication"

List of BRAF/MEK Inhibitor Combinations approved by FDA for this indication:

FoundationOne CDx
(Foundation Medicine, Inc.)
Non-Small Cell Lung Cancer (NSCLC) - TissueP170019/S033
(03/16/2022)

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor (TKI) approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

FoundationOne Liquid CDx
(Foundation Medicine, Inc.)
Non-Small Cell Lung Cancer (NSCLC) - PlasmaP190032/S008
(12/19/2022)

Non-small cell lung cancer (plasma)

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)Non-Small Cell Lung Cancer (NSCLC) - TissueP200011
(07/30/2021)

Non-Small Cell Lung Cancer (tissue):

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

MI Cancer Seek (Caris Life Sciences)Melanoma - TissueP240010 
(11/05/2024)

Melanoma (Tissue):
“Identifying patients with melanoma whose tumors have BRAF V600E and are suitable for treatment with BRAF Inhibitors approved by FDA for that indication”

List of BRAF Inhibitors approved by FDA for this indication:

MI Cancer Seek (Caris Life Sciences)Melanoma - TissueP240010 
(11/05/2024)

Melanoma (Tissue):
“Identifying patients with melanoma whose tumors have BRAF V600E and V600K and are suitable for treatment with BRAF/MEK Inhibitor Combinations approved by FDA for that indication”

List of BRAF/MEK Inhibitor Combinations approved by FDA for this indication:

MI Cancer Seek (Caris Life Sciences)Non-Small Cell Lung Cancer (NSCLC) - TissueP240010 
(11/05/2024)

Non-Small Cell Lung Cancer (tissue):

"Identifying patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and are suitable for treatment with a tyrosine kinase inhibitor approved by FDA for that indication"

List of tyrosine kinase inhibitors approved by FDA for this indication:

SUBSCRIBE

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top